These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28603635)

  • 21. Unleash innovation in foreign subsidiaries.
    Birkinshaw J; Hood N
    Harv Bus Rev; 2001 Mar; 79(3):131-7, 166. PubMed ID: 11246920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of clinical trials by Ethics Committees in Germany--results and a comparison of two surveys performed among members of the German Association of Research-Based Pharmaceutical Companies (vfa).
    Russ H; Busta S; Jost B; Bethke TD
    Ger Med Sci; 2015; 13():Doc02. PubMed ID: 25698912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors Associated with Inclusion of Japan in Phase I Multiregional Clinical Trials in Oncology.
    Maki A; Narukawa M
    Ther Innov Regul Sci; 2024 Jul; 58(4):766-772. PubMed ID: 38652349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. "Breaking the bureaucracy": drug registration and neocolonial relations in Egypt.
    Rubinstein RA
    Soc Sci Med; 1998 Jun; 46(11):1487-94. PubMed ID: 9665578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Involving South Asian patients in clinical trials.
    Hussain-Gambles M; Leese B; Atkin K; Brown J; Mason S; Tovey P
    Health Technol Assess; 2004 Oct; 8(42):iii, 1-109. PubMed ID: 15488164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Informed consent: Enforcing pharmaceutical companies' obligations abroad.
    Lee SB
    Health Hum Rights; 2010 Jun; 12(1):15-28. PubMed ID: 20930251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lessons learned conducting a multi-center trial with a military population: The Tinnitus Retraining Therapy Trial.
    Scherer RW; Sensinger LD; Sierra-Irizarry B; Formby C;
    Clin Trials; 2018 Oct; 15(5):429-435. PubMed ID: 29792074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Trial Educator program - a novel approach to accelerate enrollment in a phase III International Acute Coronary Syndrome Trial.
    Kendall B; Städeli R; Schegg B; Olbrich M; Chen E; Harmelin-Kadouri R; Aurup P; Schwab T; Hildemann SK
    Clin Trials; 2012 Jun; 9(3):358-66. PubMed ID: 22426648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Indigenous and multinational pharmaceutical companies.
    Lilja J
    Soc Sci Med; 1983; 17(16):1171-80. PubMed ID: 6623122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conducting feasibilities in clinical trials: an investment to ensure a good study.
    Rajadhyaksha V
    Perspect Clin Res; 2010 Jul; 1(3):106-9. PubMed ID: 21814631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic advantage of pharmacogenomics - clinical trials with genetic information.
    Ohashi W; Mizushima H; Tanaka H
    Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating Scientific Research Knowledge and Attitude Among Medical Representatives in Jordan: A Cross-sectional Survey.
    Mukattash TL; Alattar M; Abu-Farha RK; Alsous M; Jarab AS; Darwish Elhajji FW; Mukattash IL
    Curr Clin Pharmacol; 2017; 12(4):245-252. PubMed ID: 28847277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postgraduate Courses in Pharmaceutical Medicine in Italy.
    Criscuolo D
    Front Med (Lausanne); 2017; 4():79. PubMed ID: 28670578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial.
    Crow RA; Hart KA; McDermott MP; Tawil R; Martens WB; Herr BE; McColl E; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Hirtz D; Lochmuller H; Straub V; Ciafaloni E; Shieh PB; Spinty S; Childs AM; Manzur AY; Morandi L; Butterfield RJ; Horrocks I; Roper H; Flanigan KM; Kuntz NL; Mah JK; Morrison L; Darras BT; von der Hagen M; Schara U; Wilichowski E; Mongini T; McDonald CM; Vita G; Barohn RJ; Finkel RS; Wicklund M; McMillan HJ; Hughes I; Pegoraro E; Bryan Burnette W; Howard JF; Thangarajh M; Campbell C; Griggs RC; Bushby K; Guglieri M
    Trials; 2018 May; 19(1):291. PubMed ID: 29793540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sale strategies of pharmaceutical companies in a "pharmerging" country: the problems will not improve if the gaps remain.
    Civaner M
    Health Policy; 2012 Aug; 106(3):225-32. PubMed ID: 22682762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging role of pharmacoeconomics in the research and development decision-making process.
    DiMasi JA; Caglarcan E; Wood-Armany M
    Pharmacoeconomics; 2001; 19(7):753-66. PubMed ID: 11548911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Attitudes of general practitioners to their interactions with pharmaceutical companies: a qualitative study.
    Quinn RJ; O'Neill C
    Ir Med J; 2002; 95(7):199-202. PubMed ID: 12227525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing site performance in the Altair study, a multinational clinical trial.
    Berthon-Jones N; Courtney-Vega K; Donaldson A; Haskelberg H; Emery S; Puls R
    Trials; 2015 Apr; 16():138. PubMed ID: 25872747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.